These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 22519448)

  • 1. Matrix metallopropteinases in heart failure.
    Tousoulis D; Kampoli AM; Papageorgiou N; Antoniades C; Siasos G; Latsios G; Tsiamis E; Stefanadis C
    Curr Top Med Chem; 2012; 12(10):1181-91. PubMed ID: 22519448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of left ventricular remodelling after acute myocardial infarction: an update.
    Rossini R; Senni M; Musumeci G; Ferrazzi P; Gavazzi A
    Recent Pat Cardiovasc Drug Discov; 2010 Nov; 5(3):196-207. PubMed ID: 20874671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myocardial remodelling and matrix metalloproteinases in heart failure: turmoil within the interstitium.
    Wilson EM; Spinale FG
    Ann Med; 2001 Dec; 33(9):623-34. PubMed ID: 11817657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential novel pharmacological therapies for myocardial remodelling.
    Landmesser U; Wollert KC; Drexler H
    Cardiovasc Res; 2009 Feb; 81(3):519-27. PubMed ID: 19019834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure?
    Creemers EE; Cleutjens JP; Smits JF; Daemen MJ
    Circ Res; 2001 Aug; 89(3):201-10. PubMed ID: 11485970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of matrix metalloproteinases precedes left ventricular remodeling in hypertensive heart failure rats: its inhibition as a primary effect of Angiotensin-converting enzyme inhibitor.
    Sakata Y; Yamamoto K; Mano T; Nishikawa N; Yoshida J; Hori M; Miwa T; Masuyama T
    Circulation; 2004 May; 109(17):2143-9. PubMed ID: 15051632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implication of cardiac remodeling in heart failure: mechanisms and therapeutic strategies.
    Takano H; Hasegawa H; Nagai T; Komuro I
    Intern Med; 2003 Jun; 42(6):465-9. PubMed ID: 12857042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Matrix Metalloproteinases in Myocardial Infarction and Heart Failure.
    DeLeon-Pennell KY; Meschiari CA; Jung M; Lindsey ML
    Prog Mol Biol Transl Sci; 2017; 147():75-100. PubMed ID: 28413032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New concepts in post-infarction ventricular remodeling.
    Udelson JE; Patten RD; Konstam MA
    Rev Cardiovasc Med; 2003; 4 Suppl 3():S3-12. PubMed ID: 14564229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pacing-induced cardiomyopathy: pathophysiological insights through matrix metalloproteinases.
    Ahmed FZ; Khattar RS; Zaidi AM; Neyses L; Oceandy D; Mamas M
    Heart Fail Rev; 2014 Sep; 19(5):669-80. PubMed ID: 23856884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disruptions and detours in the myocardial matrix highway and heart failure.
    Deschamps AM; Spinale FG
    Curr Heart Fail Rep; 2005 Mar; 2(1):10-7. PubMed ID: 16036046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ethanol extract from Epimedium brevicornum attenuates left ventricular dysfunction and cardiac remodeling through down-regulating matrix metalloproteinase-2 and -9 activity and myocardial apoptosis in rats with congestive heart failure.
    Song YH; Li BS; Chen XM; Cai H
    Int J Mol Med; 2008 Jan; 21(1):117-24. PubMed ID: 18097624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of angiotensin converting enzyme inhibitors on remodeling in clinical trials.
    Greenberg BH
    J Card Fail; 2002 Dec; 8(6 Suppl):S486-90. PubMed ID: 12555162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of tissue inhibitor of metalloproteinases 2 leads to exacerbated left ventricular dysfunction and adverse extracellular matrix remodeling in response to biomechanical stress.
    Kandalam V; Basu R; Moore L; Fan D; Wang X; Jaworski DM; Oudit GY; Kassiri Z
    Circulation; 2011 Nov; 124(19):2094-105. PubMed ID: 21986284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relation between left ventricular remodeling and clinical outcomes in heart failure patients with left ventricular systolic dysfunction.
    Udelson JE; Konstam MA
    J Card Fail; 2002 Dec; 8(6 Suppl):S465-71. PubMed ID: 12555159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Type-specific dysregulation of matrix metalloproteinases and their tissue inhibitors in end-stage heart failure patients: relationship between MMP-10 and LV remodelling.
    Wei Y; Cui C; Lainscak M; Zhang X; Li J; Huang J; Zhang H; Zheng Z; Hu S
    J Cell Mol Med; 2011 Apr; 15(4):773-82. PubMed ID: 20219015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Matrix metalloproteinases, tissue inhibitors of metalloproteinases, and heart failure outcomes.
    Bhalla V; Georgiopoulou VV; Azeem AA; Marti CN; Cole RT; Laskar SR; De Staercke C; Hooper WC; Smith AL; Kalogeropoulos AP; Butler J
    Int J Cardiol; 2011 Sep; 151(2):237-9. PubMed ID: 21723628
    [No Abstract]   [Full Text] [Related]  

  • 18. Imaging of infarct healing predicts left ventricular remodeling and evolution of heart failure: focus on protease activity.
    Nahrendorf M
    Circ Cardiovasc Imaging; 2011 Jul; 4(4):351-3. PubMed ID: 21772011
    [No Abstract]   [Full Text] [Related]  

  • 19. Soluble guanylyl cyclase activation improves progressive cardiac remodeling and failure after myocardial infarction. Cardioprotection over ACE inhibition.
    Fraccarollo D; Galuppo P; Motschenbacher S; Ruetten H; Schäfer A; Bauersachs J
    Basic Res Cardiol; 2014 Jul; 109(4):421. PubMed ID: 24907870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New targets to treat the structural remodeling of the myocardium.
    González A; Ravassa S; Beaumont J; López B; Díez J
    J Am Coll Cardiol; 2011 Oct; 58(18):1833-43. PubMed ID: 22018293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.